LCTX — Lineage Cell Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.91m
- $201.01m
- $14.56m
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million
Brief: Lineage Cell Therapeutics Inc - Withdrew CIRM Grant Application Filed In June 2025 - SEC Filing
Lineage Cell Therapeutics' Q3 net loss widens, driven by warrant liabilities
Brief: Lineage Cell Therapeutics Q3 Net Income USD -29.752 Million
Brief: Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
Brief: Opregen® 36-Month Visual Acuity Results Featured At Clinical Trials At The Summit 2025
Brief: Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update
Brief: Lineage Initiates Clinical Study Of OPC1 For Spinal Cord Injury
Brief: Lineage Cell Therapeutics Announces First Closing Of Up To $66 Million Registered Direct Offering
Brief: Lineage Cell Therapeutics Announces Pricing Of Up To $66 Million Registered Direct Offering
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Brief: Opregen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
Brief: Lineage Announces Changes To Board Of Directors
Brief: Lineage Announces Appointment Of Charlotte Hubbert As Vice President Of Corporate Development
Brief: Lineage Cell Therapeutics May Offer And Sell Common Shares Of Up To $40 Million From Time To Time Through Or To B. Riley
Advisory: Alert incorrectly tagged to Lineage Cell Therapeutics withdrawn